ArticleHeliyon2024
Applicability of a green nanocomposite consists of reduced graphene oxide and β-cyclodextrin for electrochemical tracing of methadone in human biofluids validated by international greenness indexes.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Detecting methadone (MET) is crucial due to its severe side effects. Method: Herein, a green nanocomposite based on reduced graphene (rGO) and β-cyclodextrin (β-CD) has been introduced to modify a glassy carbon electrode (GCE) for real-time measurement of MET. This eco-friendly sensing interface has synergistically benefited from both advantages of rGO and β-CD including excellent electron transfer tunneling and surface area enhancement to selectively trap MET based on its shape and size. Significant findings: The developed sensor electrochemically detected MET at 0.8 V in buffer phosphate with a pH value of 7 under a wide linear concentration range (1 μM-830 μM), including a MET concentration level alarmed based on the consumer opioid tolerance according to the WHO's report. The limit of detection and analytical sensitivity values were calculated to be 333.33 nM and 0.0502 μA μM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.